IL-4R Chimeric Molecule and Interferon Combination for Ovarian Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ovarian cancer, particularly at advanced stages, are limited in effectiveness, with a high relapse rate and resistance to chemotherapy, highlighting the need for new therapeutic agents and combinations that target multiple pathways simultaneously.
Innovation Solution
The use of a combination therapy involving a chimeric molecule that binds the interleukin 4 receptor (IL-4R) with a toxic moiety, along with interferon alpha (IFNα) and interferon gamma (IFNγ), administered to treat cancers expressing IL-4R, aiming to enhance antitumor effects through synergistic action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current chemotherapy treatments are used for ovarian cancer, then some cancer cells are destroyed, but the treatment becomes ineffective due to chemotherapy resistance and high relapse rate
Solution Approach 1:
The patent combines three different therapeutic agents (chimeric molecule targeting IL-4R, interferon-alpha, and interferon-gamma) into a single treatment regimen. This multi-component combination therapy addresses chemotherapy resistance by engaging multiple distinct biological pathways simultaneously, preventing cancer cells from developing resistance to a single agent while enhancing overall treatment effectiveness.
Solution Approach 2:
The treatment regimen serves multiple functions: the chimeric molecule provides targeted cytotoxicity through IL-4R binding, interferon-alpha contributes to immune modulation and direct antiproliferative effects, and interferon-gamma enhances immune response and has direct antitumor activity. This multi-functional approach overcomes the limitations of single-agent chemotherapy by addressing both tumor cells directly and modulating the immune system.
2Productivity
If surgery and chemotherapy are used to treat advanced ovarian cancer, then visible disease is removed, but therapeutic options remain limited due to disease relapse
Solution Approach 1:
The combination therapy can be administered as adjuvant treatment following surgery to eliminate micrometastatic disease before it becomes clinically detectable. By providing targeted cytotoxicity and immune modulation in the post-surgical setting, the treatment prevents relapse by destroying residual cancer cells that standard chemotherapy may miss, thereby extending the productive effect of the initial surgical intervention.
3Measurement precision
If targeted therapies are used for ovarian cancer, then some therapeutic precision is achieved, but treatment options remain insufficient for advanced stages
Solution Approach 1:
The patent merges a targeted approach (chimeric molecule with IL-4R specificity) with broad-spectrum immunomodulatory agents (interferons). This combination maintains the precision of targeted delivery to IL-4R expressing cells while adding the versatility of immune system activation and multiple mechanisms of action, thereby expanding therapeutic options for advanced ovarian cancer without sacrificing target specificity.
Data Source
AI summary
Methods and compositions are disclosed for treating a subject with a cancer. The compositions can include a chimeric molecule comprising an agent that specifically binds the interleukin 4 receptor (IL-4R) and a toxic moiety, an interferon alpha (IFNα), and an interferon gamma (IFNγ). In some non-liming embodiments, the compositions can also include monocytes. The methods disclosed herein include administering a therapeutically effective amount of the compositions taught herein to a subject with cancer, thereby treating the cancer in the subject, wherein cells in the cancer express IL-4R. In some non-liming embodiments, the methods can also include administering monocytes.